Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

ASH Highlights

Meeting Highlights

ASH Highlights

Minimal Residual Disease After Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Meeting Highlights

ASH Highlights

Isatuximab + Pomalidomide and Dexamethasone in Frail Patients with RRMM: ICARIA-MM Subgroup Analysis

Meeting Highlights

ASH Highlights

FORTE Trial: Analysis of Survival in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

Meeting Highlights

ASH Highlights

CARTITUDE-1: Ciltacabtagene Autoleucel, a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM

Meeting Highlights

ASH Highlights

Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy, in Patients with RRMM: CRB-401 Study Updates

Meeting Highlights

ASH Highlights

Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib

Meeting Highlights

ASH Highlights

Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study

Meeting Highlights

ASH Highlights

Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Meeting Highlights

ASH Highlights

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study

Meeting Highlights

ASH Highlights

ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Page 4 of 7
Results 31 - 40 of 70